Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP.

Leslie R HarroldKeith WittstockSheila KellyXue HanYing ShanLin GuoPage C MooreVadim Khaychuk

Published in: Rheumatology and therapy (2023)

In adjusted analyses, CCP+ patients with RA initiating treatment with abatacept versus tofacitinib did not show a statistically significant difference in reducing disease activity or improving patient-reported outcomes.

Keyphrases

disease activity
rheumatoid arthritis
rheumatoid arthritis patients
patient reported outcomes
ankylosing spondylitis
systemic lupus erythematosus
juvenile idiopathic arthritis
interstitial lung disease
combination therapy